Sleepless Doctor

Lanco was founded in 1979 and is headquartered in Natick, Massachusetts. It is the world's leading medical technology company.

　　 In 1997, Lanke entered China, setting up branches and R&D centers in Imperial Capital, Magic Capital, and Yangcheng. The company's headquarter in China is in Magic Capital.

　　 Orchid's core business areas in China are cardiac intervention, cardiac rhythm management and electrophysiology, structural heart disease, endoscopic intervention, respiration, peripheral and tumor intervention, etc.

　　 As the world's leading provider of innovative medical solutions, Lanco is committed to long-term investment in innovative research and development.

　　 Lanco has more than 13,000 products and has obtained more than 16,000 authorized patents worldwide. In 2013, Lanco's R&D investment reached 861 million U.S. dollars, making it one of the medical device companies with the largest R&D investment in the world.

　　 In the process of the rise of domestic cardiovascular interventional surgery, Poco has made huge excess profits and made a lot of money.

　　 And their ambitions don't stop there. Both Johnson & Johnson and Medtronic are one step ahead of Lanco in business promotion and technology.

　　 Therefore, Orchid has recently invested a large amount of money to produce consumables for interventional minimally invasive treatment of mitral regurgitation, and it has entered the fourth phase of clinical trials.

　　 If this business is promoted, Lanco is confident that it will become the leader in cardiac interventional consumables in the United States and even the world.

　　……

　　……

　　 In the office of the CEO of Lanco's headquarters in Natick, Massachusetts, Jack Jones actually signs the document.

　　 The company’s recent research is in trouble, which upsets Jack Jones.

　　 There is a study on high-value consumables for mitral valve clamping under interventional surgery, which is a huge profit growth point for Lanco, and it is the company's hope.

　　From the establishment of the project in 2002 to the approval of the FDA in 2013, it has gone through untold hardships and invested huge amounts of money.

　　 One week after approval, Professor Saibal　Kar, deputy director of the Cardiovascular Intervention Center of Cedar-Sinai Medical Center, completed the first mitral valve clamping operation in the United States for the treatment of heart valve diseases that threaten the lives of patients.

　　 All of these seem so perfect. Continuous technological advancement is the best way to obtain excess profits. No one knows this.

　　 But technological progress is so difficult, Lanco relied on the world's top three circular intervention high-value consumables to barely support the excess income.

　　 I thought that after being approved by the FDA in 13 years, mitral valve clamping surgery could be promoted smoothly around the world, but in the end the key to the operation was the technology.

The consumables developed by 　　Orchid are mainly used for patients with mitral regurgitation whose reflux is located in the "A2P2" area, and it is required that these two areas have no obvious calcification or valvular fissure.

　　The latter is not difficult, but the requirement of A2P2　 area reflux restricts most operations.

　　Saibal　Kar, a cardiac intervention specialist at Cedarsene Medical Center in the United States, is the completer of the first MitraClip clinical in the United States and works closely with Orchid.

　　 He completed aClip in 2017, ranking first in the world in terms of surgery volume.

　　 is the number one in the world, which makes Lanco extremely troublesome.

　　 The minimally invasive surgical procedure for the treatment of mitral regurgitation, which has spent huge sums of money, has only 133 cases completed by doctors in the world! ! !

　　 Lanco can't stand this kind of thing.

　　 The technical department wants to improve the technology and strive to make all patients with mitral regurgitation suitable for surgery. But a few years later, the indications for surgery are still limited to mitral regurgitation in the A2P2　 area.

　　 Judging from the current situation, there is no way to recover the huge research costs, let alone excess profits.

　　 This is a headache that every pharmaceutical and consumable company has to face.

　　 It is often heard that multinational pharmaceutical companies fail to recover because of the failure of a promising project with huge investment.

　　 Although Lanco is not going to go bankrupt, the situation they face is still not optimistic.

　　 This company has made many adjustments, and the technical department seems to be working hard to improve, and it is looking for world-renowned circulatory intervention surgeons to conduct joint research.

However,

　　 The result was disappointing.

　　 "咚咚咚~"

　　 There was a knock on the door.

　　 "Mr. Jones, there is a new mail." The door opened, and Jack Jones' assistant bowed slightly and said politely.

　　 "Whose? What content?" Jack Jones didn't look up, he was reviewing the new season's earnings report.

　　 "It's an email from Dr. Wu from Massachusetts General Hospital..."

　　 "No matter what he says, he refuses." Seb Carr said coldly.

　　The assistant hesitated. He didn't know why the world's top doctors who had been invited by the company several times before sent emails, but Mr. Jack Jones didn't even think about it, so he refused.

　　 After hesitating, the assistant bowed and left.

　　 Just as the door was about to close, he couldn't help but said, "Mr. Jones..."

　　 "What?" Jack Jones raised his head and helped his glasses, his eyes already showing unhappiness.

　　 "You really don't read the mail."

　　 "No, I'm busy." Jack Jones said nothing, and continued to look down at the financial report.

　　 "Mr. Carl... Wu said he can do full mitral valve surgery." The assistant couldn't help but said.

　　 "Reject him..." After half a sentence, Seb Carr raised his head in surprise and looked at his assistant, "What did you say? What did Wu say in the email?"

　　 "Wu said in the e-mail that he found a way to do total mitral valve surgery." Jack Jones' assistant said ~www.wuxiaspot.com~Jack Jones was stunned.

　　The so-called total operation is a type of operation that can be used by all patients with mitral regurgitation, unlike the dilemma faced by the company now, which can only treat patients with mitral regurgitation in the A2P2 area.

　　 All-surgery style!

　　 This is what Lanco has been pursuing!

　　 Jack Jones was shining with gold, as if it was the era of the big gold rush, he found a river full of gold sand by himself.

　　 "Print out the email immediately and give it to me." Jack Jones seems to have forgotten what he said before.

　　 "Okay, Mr. Jones." His assistant bowed and left.

　　 A few minutes later, Jack Jones held the mail in his hand and looked at it word by word.

　　 The young man said that he has passed animal experiments and can complete a full-scale mitral regurgitation operation. As long as Lanco agrees, cooperation can be started.

　　 Of course, Wu directly explained what he needed in the email.

　　 Interventional consumables for congenital heart disease, which is not difficult for Poko. Although the selling price is high, the cost price is very low.

　　 What makes Jack Jones the most unacceptable is that Wu actually said that he would not come to Natick and asked Poco to establish the research institute in an unknown place.

　　 Agree or disagree, this is a question.

　　 Such an important matter must pass the board of directors, and Jack Jones finally made such a decision.